Evolving Concepts in Atopic Dermatitis

• Published in: Current allergy and asthma reports Vol. 17; no. 7; p. 42
• Main Authors: Sidbury, Robert, Khorsand, Kate
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.07.2017; Springer Nature B.V
• Subjects: Allergic Skin Diseases (L Fonacier; Allergology; Animals; Comorbidity; Cost of Illness; Dermatitis; Dermatitis, Atopic - economics; Dermatitis, Atopic - epidemiology; Dermatitis, Atopic - immunology; Dermatitis, Atopic - therapy; Eczema; Humans; Immunotherapy; Medicine; Medicine & Public Health; Monoclonal antibodies; Pathogenesis; Section Editor; Topical Collection on Allergic Skin Diseases; Atopic dermatitis; Anemia; Attention deficit hyperactivity disorder; Filaggrin; Crisaborole; Emollient; Dupilumab; Quality of life
• ISSN: 1529-7322; 1534-6315
• DOI: 10.1007/s11882-017-0710-5

Purpose of Review Tremendous advances have been made in the field of atopic dermatitis in the past 5 years. We will explore developments in burden of disease, co-morbidities, pathogenesis, prevention, and management. Recent Findings The tremendous burden moderate to severe atopic dermatitis (AD) places on families from a medical, psychosocial, and financial perspective has been characterized. Epidemiologic studies have identified intriguing new associations beyond the well-characterized “atopic march” of food allergies, asthma, and hay fever. Studies of primary prevention have gained traction including the remarkable impacts of early emollient therapy. Basic advances have simultaneously elucidated the nature of atopic inflammation, setting the stage for an explosion of new potential therapeutic targets. After a fallow period of nearly 15 years without a substantial therapeutic advance, this year has already seen two new FDA-approved treatments for AD. Summary AD has a tremendous impact on quality of life with an underappreciated burden of disease; there are important newly described co-morbidities including ADHD and anemia; new insights into etio-pathogenesis have paved the way for novel topical therapies like crisaborole, and new systemic interventions like dupilumab.